GlassScriptPhysician profile
Fariborz Shams
NPI 1063421865
$65,288.64
in general payments reported to CMS, 2019-2025
54 companies · $9,347 in 2025
The $9,347 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $5,567 · 2021: $3,068 · 2022: $5,654 · 2023: $3,128 · 2024: $21K · 2025: $9,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $3,088 · Travel and Lodging: $1,455 · Honoraria: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,425.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,500.00 |
| Food and Beverage | $3,088.25 |
| Travel and Lodging | $1,454.94 |
| Honoraria | $1,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $25,578.38 | 2022-2025 | Ingrezza, Ongentys |
| Janssen Pharmaceuticals, INC | $16,974.26 | 2019-2024 | Xarelto |
| Edwards Lifesciences Corporation | $8,275.00 | 2019-2023 | |
| Becton, Dickinson and Company | $4,125.00 | 2024-2025 | Hemosphere |
| Novo Nordisk INC | $1,757.80 | 2019-2022 | |
| Urovant Sciences INC | $1,136.81 | 2022 | |
| Novartis Pharmaceuticals Corporation | $949.70 | 2019-2024 | |
| Avanir Pharmaceuticals, INC. | $945.68 | 2019-2022 | |
| Verathon INC. | $500.00 | 2022 | |
| Hill-Rom Services, INC | $450.00 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $421.28 | 2022-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Lilly USA, LLC | $348.14 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $323.35 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.15 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Sanofi-Aventis U.S. LLC | $263.25 | 2019-2025 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fariborz Shams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.